News

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...
The FDA's vaccine advisory committee meeting to prepare for next year's flu season has been canceled. Zelenskyy explains his position after disrupted meeting with Trump Former SpaceX employee ...
You can reach Lizzy on Signal at lizzylaw.53. The Food and Drug Administration canceled an upcoming vaccine advisory committee meeting to discuss influenza virus strains, according to committee ...
The FDA's Vaccines and Related Biological Products Advisory Committee was scheduled for next month. But the agency notified committee members that the meeting had been canceled. The Food and Drug ...
Pitts, a former FDA associate commissioner, was the agency’s senior official in charge of advisory committees. During my time at the Food and Drug Administration, I was the senior official in ...
The company said the FDA is considering holding an advisory committee meeting, though the agency provided no official date. Capricor CEO Linda Marbán said the company has been “actively ...
The FDA will hold its first Digital Health Advisory Committee (DHAC) meeting to discuss how the agency should review medical devices that rely on generative AI, like chatbots. The meeting will be ...
"A planned March 13 meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee on the influenza vaccine strains for the 2025-2026 influenza season in the northern ...
13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC ... to today’s meeting, and will continue to work collaboratively with the FDA on behalf of patients.
In recent years, several senior FDA officials have publicly hinted at possible advisory committee reforms, following increased attention to advisory committee meetings during the COVID-19 pandemic ...
The FDA's Advisory Committee calendar, updated as of Wednesday, shows no March meetings scheduled. As for the VRBPAC specifically, its "meeting materials" archive shows no content for the current ...
- Columvi is the first bispecific antibody to show a statistically significant and clinically meaningful 41% survival benefit in R/R DLBCL in the Phase III STARGLO study - - There is an urgent ...